🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT03373721
Recruiting Observational

Gut Microbiota of Preterm Infants and Full-term Infants at Early Life

NCT03373721 · tracked via the Priya Life Science China tracker
Sponsor
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Phase
Observational
Started
2014-07-20
Last updated
2024-04-17

Condition(s) studied

Preterm InfantGut Microbiome

Study summary

The aim of this study is to obtain a longitudinal view of the gut microbial establishment of a cohort of 51 preterm (PT) infants compared to 50 full-term (FT) infants from birth to 90 days of age, and to identify key clinical factors that affect the establishment of neonatal microbiome.

The hypothesis of the investigators is that the gut microbiota progression of PT group and FT group is different in diversity and composition. Antibiotics and its usage duration is likely the main factor disturbing the colonization and development of the gut microbiome of PT infants.

Eligibility

Sex
ALL
Min age
1 Day
Max age
4 Months
Healthy volunteers
Accepted
Inclusion Criteria: Preterm infants 1. gestational age \<37 weeks; 2. no gastrointestinal tract disorders, metabolic diseases, or viral hepatitis; 3. hospital stay \> 7 days; Exclusion criteria: 1. NICU stay less than 7 days 2. Necrotizing enterocolitis infant Control group: 1. Full-term healthy infants; 2. gestational age \>37 weeks; 3. vaginally born; 4. no gastrointestinal tract disorders, metabolic diseases, or viral hepatitis.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Department of NICU, XinHua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Shanghai China Recruiting

More Xinhua Hospital, Shanghai Jiao Tong University School of Medicine trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03373721 on ClinicalTrials.gov ↗ ← All trials in China